-
Inovio's HIV Vaccine Elicits High Response Rates In Phase 1 Trial
Thursday, May 25, 2017 - 12:15pm | 563Read More...Following the results release of an early-stage study of Pennvax-GP, Inovio Pharmaceuticals Inc (NASDAQ: INO)'s HIV vaccine, H.C. Wainwright noted that the vaccine elicited high T-cell and antibody immune responses in healthy and uninfected adults. The Trial Analysts Raghuram Selvaraju and Yi Chen...


